With four new drug approvals notched under its belt in four months, GlaxoSmithKline had several potential growth drivers to highlight during its third quarter earnings call, helping to deflect attention away from the bribery scandal in China.
GlaxoSmithKline PLC’s new drug approvals in core areas demonstrate the big pharma is delivering on its R&D promises and establishing near-term sales, CEO Andrew Witty said during the company’s third quarter sales and earnings call Oct. 23. But a bribery scandal in China overshadowed any positive news.
An ongoing bribery scandal and government investigation has impacted the company’s ability to sell drugs in the country. The company’s...
Sun’s founder hands top job to company longtimer Kirti Ganorkar as the firm implements a “structured and forward-looking” succession plan, while Richard Ascroft will lead the Indian drugmaker’s North America business.
After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.
Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?
